Myriad Genetics expanded access to faster hereditary cancer testing for ovarian and endometrial cancer patients, the company announced during Ovarian Cancer Awareness Month as part of its broader oncology diagnostics push.
published
Myriad Genetics expanded access to faster hereditary cancer testing for ovarian and endometrial cancer patients, the company announced during Ovarian Cancer Awareness Month as part of its broader oncology diagnostics push.
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.